Available options in chemotherapy for advanced gastric cancer: The current developments in Japan

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 2, 2005, Pages 225-231

  Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced gastric cancer; S 1; Standard chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CAPECITABINE; CARMOFUR; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; TAXANE DERIVATIVE; TEGAFUR; TS 1; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; EUROPE; GASTROINTESTINAL TOXICITY; HUMAN; JAPAN; KOREA; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; REVIEW; STANDARDIZATION; STOMACH CANCER; TREATMENT PLANNING; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DOXORUBICIN; FLUOROURACIL; JAPAN; METHOTREXATE; STOMACH NEOPLASMS;

EID: 14644424630     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.2.225     Document Type: Review

References (42)

1. MACDONALD JS, SCHEIN PS, WOOLLEY PV et al.: 5-fluorouracil, mitomycin-C, and Adriamycin (FAM): A new combination chemotherapy program for advanced gastric carcinoma. Ann. Intern. Med. (1980) 93:533-536.
2. DUSCHINSKY R, PLEVEN E, HEIDELBERGER C et al.: The synthesis of 5-fluoropyrimidines. J. Am. Chem. Soc. (1957) 79 4559-4560.
3. WILS J, KLEIN DJ, WAGENER TH et al.: Sequential high dose methotrexate and 5-fluorouracil combined with doxorubicin-A step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. (1991) 9:827-831.
4. KELSEN D, ATIQ OT, SALTZ L et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. (1992) 10(4):541-548.
5. MURAD AM, SANTIAGO FF, PETROIANU A et al.: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (1993) 72:37-41.
6. KIM NK, PARK YS, HEO DS et al.: A phase randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer (1993) 71:3813-3818.
7. WEBB A, CUNNINGHAM D, SCARFFE JH et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. (1997) 15(1):261-267.
8. VANHÖEFER UV, ROUGIER P, WILKE H et al.: Final results of a randomized phase trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. (2000) 18(14):2648-2657.
9. AJANI JA, VAN CUTSEM E, MOISEYENKO V et al.: Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase trial (V 325). Proc. Am. Soc. Clin. Oncol. (2003) 22:249 (Abstract).
10. AJANI JA, OTA DM, JACKSON DE et al.: Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer (1991) 67:260-265.
11. TAKAUCHI H, AJANI JA: Uracil-tegafur in gastric carcinoma: a comprehensive review. J. Clin. Oncol. (1998) 16:2877-2885.
12. NIITANI H, KURIHARA M, SAITO T et al.: Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer - multi-institutional cooperative study. Jpn. J. Cancer Chemother. (1989) 12:2044-2051.
13. SAKATA Y, YOSHIDA Y: Phase II study of epirubicin in inoperable or recurrent gastric cancer. Japan J. Cancer Chemother. (1980) 13:1887.
14. ISIBIKI K, KUMAI K, KODAIRA S et al.: Phase II study with cisplatin in advanced stomach and colon cancer. Jpn. J. Cancer Chemother. (1989) 16:3185-3193.
15. FUTATSUKI K, WAKUI A, NAKAO I et al.: Late Phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn. J. Cancer Chemother. (1994) 21:1033-1038.
16. SHIRASAKA T, SHIMAMOTO Y, OHSHIMO H et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulation. Anti Cancer Drugs (1996) 7 548-557.
17. SCHOEFFSCII P: The modulated oral fruoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs (2004) 15:85-106.
18. SOBRERO A, KRR D, GLIMELIUS B et al.: New directions in the treatment of colorectal cancer: a look to the future. Eur. J. Cancer (2000) 36:559-566.
19. SUGIMACHI K, MAEHARA Y, HIROKOSHI N et al.: An early Phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology (1999) 57:202-210.
20. SAKATA Y, OHTSU A, HORIKOSHI N et al.: Late phase study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J. Cancer (1998) 34:1715-1720.
21. KOIZUMI W, KURIHARA M, NAKANO S et al.: Phase II study of S-1 a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology (2000) 58:191-197.
22. MAEHARA Y: S-1 in gastric cancer: a comprehensive review. Gastric Cancer (2003) 6(Suppl. 1):2-8.
23. KOIZUMI W, SAIGENJI K, UJIIE S et al.: A pilot phase study of capecitabine in advanced or recurrent gastric cancer. Oncology (2003) 64:232-236.
24. CHIN K, KONDO K, SAKAMOTO J et al.: Late Phase II study of Ro09-1978 (capecitabine) for advanced gastric cancer. Proc. Jpn. Soc. Clin. Oncol. (2003) 38:449 (Abstract).
25. TAGUCHI T, SAKATA Y, KANAMARU R et al.: Late Phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group Trial (Group A). Jpn. J. Cancer Chemother. (1998) 25:1915-1924.
26. MAI M, SAKATA Y, KANAMARU R et al.: A late Phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Japanese Cooperative Study Group Trial (Group B). Jpn. J. Cancer Chemother. (1999) 26:487-496.
27. YAMAGUCHI K, TADA M, HORIKOSHI N et al.: Phase II study of pacritaxel with 3-hour infusion for advanced gastric cancer. Gastric Cancer (2002) 5:90-95.
28. YAMADA Y, SHIRAO K, OHTASU A et al.: Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis of paclitaxel associated hypersensitivity reactions. Ann. Oncol. (2001) 12:1133-1137.
29. KURIHARA M IZUMI T, YOSHIDA S et al.: A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn. J. Cancer Res. (1991) 82:613-620.
30. OHTSU A, SHIMADA Y, YOSHIDA S et al.: Phasestudy of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan clinical oncology group (JCOG). Eur. J. Cancer (1994) 30A:2091-2093.
31. OHTSU A, SHIMADA Y, SHIRAO K et al.: Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus cisplatin plus tegafur plus mitomycin C in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. (2003) 21:54-59.
32. KURIHARA M: Relationship between quality of life and survival in patients undergoing two therapeutic regimens with 5′-DFUR and CDDP for inoperable advanced gastric cancer - report of a Phase II study. Proceedings of the society for survival time studies on cancer patients (1993) 13(1):39-42
33. KOIZUMI W, KURIHARA M, SASAI T et al.: A phase study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer (1993) 72:658-662.
34. SATO A, KURIHARA M, KOIZUMI W et al.: A phase study of UFT plus cisplatin (UFTP) therapy in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:279A (Abstract).
35. KOIZUMI W, TANABE S, SAIGENJI K et al.: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer (2003) 89:2207-2212.
36. NAKATA B, MITACHI Y, AKIHIKO T et al.: Combination Phase Trial of A Novel Oral Fluorouracil Derivative S-1 with Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902). Clin. Cancer Res. (2004):1664-1669.
37. HYODO I, NISHINA T, MORIWAKI T et al.: A Phase study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur. J. Cancer (2003) 39:2328-2333.
38. KOMATSU Y, TAKEI M, TAKEDA H et al.: Phase II study of CPT-11 plus S-1 in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:1282 (Abstr.).
39. NARAHARA H, TAKIUCHI H, TSUJINAKA T et al.: Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:170a (Abstract).
40. BOKU N, OHTSU A, SHIMADA Y et al.: Phase I study of combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. (1999) 17:319-323.
41. KOIZUMI W, KURIHARA M, SATOH A et al.: Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Research (2005) In press.
42. AJANI JA: Standard chemotherapy for gastric carcinoma:is it a myth? J. Clin. Oncol. (2000) 18(23):4001-4003.